Arax Advisory Partners’s Zimmer Biomet ZBH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.79M Buy
19,826
+19,287
+3,578% +$1.77M 0.05% 298
2025
Q4
$48.4K Sell
539
-25,562
-98% -$2.42M ﹤0.01% 1626
2025
Q3
$2.57M Buy
26,101
+25,068
+2,427% +$2.48M 0.04% 402
2025
Q2
$94.2K Buy
1,033
+838
+430% +$81K ﹤0.01% 957
2025
Q1
$22.1K Sell
195
-284
-59% -$30.4K ﹤0.01% 1262
2024
Q4
$50.6K Buy
479
+285
+147% +$30.6K ﹤0.01% 896
2024
Q3
$20.9K Buy
194
+5
+3% +$546 ﹤0.01% 1066
2024
Q2
$20.5K Buy
189
+182
+2,600% +$21.5K ﹤0.01% 953
2024
Q1
$924 Hold
7
﹤0.01% 1165
2023
Q4
$852 Buy
7
+5
+250% +$558 ﹤0.01% 1151
2023
Q3
$225 Buy
+2
New +$254 ﹤0.01% 1279
2020
Q3
Sell
-26
Closed -$3K 718
2020
Q2
$3K Buy
+26
New +$3K ﹤0.01% 623
2018
Q3
Sell
-11
Closed -$1K 747
2018
Q2
$1K Sell
11
-2
-15% -$218 ﹤0.01% 480
2018
Q1
$1K Buy
+13
New +$1.51K ﹤0.01% 472
2017
Q2
Sell
-14
Closed -$1K 539
2017
Q1
$1K Buy
+14
New +$1.59K ﹤0.01% 526

Other funds holding ZBH

Arax Advisory Partners's ZBH Position: Q1 2026 in Review

Arax Advisory Partners increased its Zimmer Biomet (ZBH) stake by 3,578% in Q1 2026, buying an estimated $1.77M and bringing the position to 19,826 shares worth $1.79M. The position accounts for 0.05% of the portfolio, ranked #298.

Arax Advisory Partners first reported a position in ZBH in Q1 2017 and has held it in 15 quarters since. The position peaked at $2.57M in Q3 2025. 912 funds tracked by Wall St. Rank hold ZBH as of Q1 2026.

  • Arax Advisory Partners held 19,826 shares of Zimmer Biomet worth $1.79M as of Q1 2026.
  • Arax Advisory Partners bought 19,287 Zimmer Biomet shares in Q1 2026, an estimated $1.77M.
  • Zimmer Biomet made up 0.05% of Arax Advisory Partners's portfolio in Q1 2026, its #298 holding.
  • Arax Advisory Partners first reported a position in Zimmer Biomet in Q1 2017 and has held it in 15 quarters since.
  • Arax Advisory Partners's Zimmer Biomet position peaked at $2.57M in Q3 2025.
  • 912 funds tracked by Wall St. Rank held Zimmer Biomet as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.